An interventional study of Therapeutic Ultrasound and Intra-articular corticosteroid injection in Arthritis, Ultrasonication and Intra-articular Injections, sponsored by Taichung Veterans General Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Taichung Veterans General Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Arthritis with a site in Taiwan — 3 open to participants now, 4 under way, 1 of them phase 3. Arthritis · Taiwan.
Among the 16 studies in Arthritis with a site in Taiwan, this one is the 13th largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2026, is one of 3 with no phase, and was the 16th registered.
843 studies on the registry are indexed under Arthritis; 118 are open to participants now.
Browse Arthritis studies →3 of the 16 studies in Arthritis with a site in Taiwan are open now. Recruiting first, the newest first:
Chung Shan Medical University · Sites in Taiwan
Ages 45–80
Buddhist Tzu Chi General Hospital · Sites in Taiwan
Ages 20–99
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 78 Arthritis studies recruiting now, 41 (53%) set no upper age limit and 20 (26%) stop at 75 or younger; 16 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is close to the median of 97 across 599 interventional studies indexed under Arthritis.
Median enrollment 529 across the 15 interventional studies, 992 across the 1 observational. Of the 11 that completed or were terminated, 11 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 16 have an industry lead sponsor. The 9 most frequent:
Taichung Veterans General Hospital is the lead sponsor of 176 studies on the registry; 39 are open to participants now.
Taichung Veterans General Hospital has 1 study filed under Arthritis — fewer than ten, so there is no comparison to draw.
2 of the studies in Arthritis with a site in Taiwan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07363876Taichung Veterans General HospitalThe Efficacy of Ultrasonication in Combination With Corticosteroid Intraarticular Injection for Arthritis | 2026-11-30 |
| NCT06658821Chung Shan Medical UniversityThe Effect of LDL557 on Improving Degenerative Arthritis in the Elderly | 2027-06-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 16 studies in Arthritis with a site in Taiwan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study investigates whether ultrasound therapy applied prior to intra-articular corticosteroid injection can enhance the treatment efficacy for patients with joint arthritis and assess its safety. Adult patients diagnosed with arthritis in the limbs who are indicated for corticosteroid injection are eligible, while patients with joint replacement, hip joint involvement, gout, infectious arthritis, or local cellulitis are excluded.
Ultrasound therapy is a valuable physical therapy tool for musculoskeletal diseases, producing therapeutic effects through thermal and non-thermal mechanisms. It can improve tissue extensibility, reduce joint stiffness, increase local blood flow, enhance metabolism during tissue repair, and facilitate drug absorption. This study evaluates whether applying ultrasound before intra-articular corticosteroid injection improves therapeutic outcomes in patients with arthritis, and assesses the safety of this combined intervention. Patients aged 18 or older, diagnosed with limb arthritis, and indicated for corticosteroid injection are eligible. Exclusion criteria include joint replacement, hip joint involvement, gout, infectious arthritis, or local cellulitis at the treatment site.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Therapeutic Ultrasound · Procedure: Intra-articular corticosteroid injection
Procedure: Intra-articular corticosteroid injection
Therapeutic Ultrasound (TUS) is a non-invasive treatment widely used in physical medicine and rehabilitation for musculoskeletal conditions. Since its introduction in the mid-20th century, TUS has gained popularity in clinical practice due to its ability to penetrate tissues, target treatment areas precisely, and exhibit minimal side effects. This study aims to investigate the mechanisms of action, clinical efficacy, and safety of therapeutic ultrasound in musculoskeletal therapy.
Injection of triamcinolone (3-50 mg depending on joint size) into the affected joint. Administered once per participant.
Reduction in Synovial Swelling Area Assessed by Joint Ultrasound
Synovial swelling area (pixels) assessed by joint ultrasound. A treatment response is defined as a ≥50% reduction in synovial swelling area from baseline.
Time frame: From enrollment to the end of treatment at 2 weeks
Change in Power Doppler (PD) Score of the Target Joint
Power Doppler (PD) score (range 0-3) of the target joint assessed by joint ultrasound. A treatment response is defined as a PD score of 0 at 2 weeks post-treatment.
Time frame: From enrollment to the end of treatment at 2 weeks
Change in Pain Visual Analogue Scale (VAS)
Pain intensity assessed using a visual analogue scale (VAS 0-10). A treatment response is defined as a ≥50% reduction in VAS score from baseline or a VAS score ≤1 at 2 weeks post-treatment.
Time frame: From enrollment to the end of treatment at 2 weeks
Absence of Synovitis Recurrence Based on Power Doppler (PD) Score
Absence of synovitis recurrence assessed by Power Doppler (PD) ultrasound. Recurrence is defined as any increase in PD score compared with the 2-week post-treatment assessment.
Time frame: From enrollment to 3 months post-treatment
Absence of Synovial Swelling Recurrence on Gray-Scale Ultrasound
Absence of synovial swelling recurrence assessed by gray-scale ultrasound. Recurrence is defined as an increase in synovial swelling area of ≥20% compared with the 2-week post-treatment assessment.
Time frame: From enrollment to 3 months post-treatment
Started Feb 2026 (actual). Primary completion is estimated for Nov 2026, 9 months after the start.
Of 133 non-industry interventional studies with no phase under Arthritis, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 57. This study's planned 9 months is below that.
Counting every sponsor, half of 166 studies reached it within 31 months; a quarter within 13 and three quarters within 65.
Start moved once since we started tracking on Sep 25, 2026: Dec 2025 → Feb 2026, on Sep 30, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Taichung Veterans General Hospital →